MS drug ibudilast demonstrated a 26% reduction in confirmed disability progression in progressive MS trial
Biopharmaceutical Company MediciNova has announced additional positive clinical data from its SPRINT-MS phase IIB trial of MN-166 (ibudilast) in progressive multiple sclerosis (PMS)...Read more - http://www.ms-uk.org/ms-drug-ibudilast- ... e-ms-trial
Ibudilast 26% reduction in confirmed disability progression
Ibudilast 26% reduction in confirmed disability progression
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1964 Views
-
Last post by frodo
-
- 0 Replies
- 697 Views
-
Last post by frodo
-
- 0 Replies
- 1119 Views
-
Last post by NHE
-
- 0 Replies
- 2505 Views
-
Last post by NHE
-
- 0 Replies
- 1437 Views
-
Last post by NHE
-
- 0 Replies
- 1510 Views
-
Last post by NHE
-
- 0 Replies
- 1171 Views
-
Last post by frodo
-
- 0 Replies
- 1225 Views
-
Last post by NHE
-
- 4 Replies
- 1356 Views
-
Last post by Scott1